Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for LCR/HCR rat mitochondrial study (Study ST000671)

C18 NEGATIVE ION MODE (Analysis AN001028)

Metabolite	Structure	F1	F2	F3	F4
PC 42:1; [M-Ac-H]-@9.17	ME184213	0.71	0.51	0.41	2.37
PG 40:7; [M-H]-@5.00	ME184269	1.68	1.00	0.68	0.64
PG 42:10; [M-H]-@4.53	ME184271	0.86	1.52	0.69	0.94
plasmenyl-PE 36:1; [M-H]-@7.69	ME184302	0.90	0.73	0.63	1.75
plasmenyl-PE 38:1; [M-H]-@8.23	ME184306	0.88	0.59	0.79	1.74
lysoPE 18:1; [M-H]-@1.78	ME184290	0.83	0.94	0.80	1.42
plasmenyl-PE 35:1; [M-H]-@7.48	ME184301	0.88	0.92	0.81	1.39
plasmenyl-PE 38:2; [M-H]-@7.85	ME184307	1.05	0.76	0.76	1.43
PC 35:0; [M-Ac-H]-@7.65	ME184192	1.04	0.73	0.85	1.38
PE 38:2; [M-H]-@7.51	ME184231	0.97	0.71	0.87	1.45
plasmenyl-PE 34:3; [M-H]-@6.33	ME184300	1.00	0.69	0.91	1.40
PC 31:0; [M-Ac-H]-@6.23	ME184182	0.66	1.16	1.03	1.15
CL 74:11; [M-2H](2-)@8.68	ME184159	0.71	0.95	1.19	1.14
plasmenyl-PE 32:1; [M-H]-@6.56	ME184295	0.62	0.86	1.28	1.24
Arachidonic acid	ME184146	1.16	1.10	1.13	0.60
PC 33:2; [M-Ac-H]-@6.02	ME184188	1.25	0.93	1.18	0.65
PE 33:2; [M-H]-@6.06	ME184218	1.18	1.29	0.91	0.62
PC 42:8; [M-Ac-H]-@6.38	ME184215	1.22	1.22	0.80	0.76
PG 40:8; [M-H]-@4.56	ME184270	1.32	1.14	0.80	0.73
PC 35:3; [M-Ac-H]-@6.14	ME184194	0.92	1.01	1.25	0.82
CL 68:1; [M-2H](2-)@7.25	ME184148	0.88	1.27	1.06	0.79
PC 33:1; [M-Ac-H]-@6.45	ME184187	0.71	1.20	1.18	0.91
plasmenyl-PE 33:0; [M-H]-@7.35	ME184296	1.27	1.05	0.70	0.98
plasmenyl-PE 36:3; [M-H]-@6.91	ME184303	1.18	1.01	0.76	1.05
PC 30:0; [M-Ac-H]-@5.98	ME184180	1.42	0.91	0.78	0.89
PE 34:2; [M-H]-@6.36	ME184221	1.43	0.95	0.77	0.85
PC 33:0; [M-Ac-H]-@6.82	ME184186	1.41	0.92	0.88	0.80
PE 34:0; [M-H]-@6.87	ME184219	1.35	0.91	0.98	0.76
PI 40:4; [M-H]-@6.23	ME184281	1.36	0.81	0.97	0.86
PE 38:3; [M-H]-@7.23	ME184232	1.27	0.92	0.95	0.86
PG 32:0; [M-H]-@5.67	ME184250	1.29	0.85	0.94	0.92
CL 70:6; [M-2H](2-)@8.99	ME184152	0.82	0.91	1.22	1.04
PE 41:6; [M-H]-@7.06	ME184246	0.91	0.83	1.24	1.02
PI 38:2; [M-H]-@6.35	ME184277	0.86	0.79	1.17	1.19
plasmenyl-PE 34:1; [M-H]-@7.12	ME184298	0.95	0.72	1.10	1.23
lysoPE 22:6; [M-H]-@1.21	ME184293	0.96	0.88	1.11	1.04
PC 36:0; [M-Ac-H]-@7.97	ME184197	1.01	0.86	1.06	1.07
PG 38:4; [M-H]-@5.98	ME184265	0.91	0.90	1.07	1.11
CL 72:9; [M-2H](2-)@8.68	ME184158	0.97	0.83	1.03	1.16
PC 38:2; [M-Ac-H]-@7.54	ME184205	0.97	0.88	1.00	1.14
CL 78:13; [M-2H](2-)@8.85	ME184165	0.97	0.77	1.16	1.09
PE 32:1; [M-H]-@6.19	ME184217	0.97	0.72	1.19	1.12
PG 38:3; [M-H]-@6.04	ME184264	1.05	0.80	1.04	1.11
CL 66:1; [M-2H](2-)@6.21	ME184147	1.02	0.78	1.11	1.09
PC 37:2; [M-Ac-H]-@7.25	ME184202	1.05	0.77	1.12	1.06
PE 36:1; [M-H]-@7.41	ME184224	0.89	1.14	0.93	1.04
PG 44:12; [M-H]-@4.41	ME184272	0.95	1.10	0.96	0.99
PE 32:0; [M-H]-@6.68	ME184216	0.94	1.15	0.85	1.05
plasmenyl-PE 36:4; [M-H]-@6.64	ME184304	0.93	1.08	0.89	1.10
CL 70:7; [M-2H](2-)@8.79	ME184153	0.93	0.97	0.90	1.20
FFA(24:0)	ME184178	0.94	1.00	0.89	1.17
plasmenyl-PE 38:4; [M-H]-@7.22	ME184309	0.96	1.00	0.89	1.15
plasmenyl-PE 36:5; [M-H]-@6.29	ME184305	0.88	1.03	0.83	1.26
plasmenyl-PE 38:3; [M-H]-@7.53	ME184308	0.90	1.07	0.81	1.21
CL 80:15; [M-2H](2-)@9.10	ME184166	1.21	1.02	0.98	0.78
PE 38:5; [M-H]-@6.48	ME184234	1.17	0.98	0.99	0.86
plasmenyl-PE 34:0; [M-H]-@7.64	ME184297	1.17	1.02	1.00	0.82
plasmenyl-PE 40:5; [M-H]-@7.33	ME184313	1.14	1.03	0.99	0.84
PG 35:1; [M-H]-@6.07	ME184256	1.10	1.09	1.00	0.81
PG 34:1; [M-H]-@5.69	ME184254	1.18	1.08	0.94	0.80
PE 34:3; [M-H]-@5.93	ME184222	1.13	1.14	0.94	0.80
PE 39:6; [M-H]-@6.50	ME184239	1.12	1.12	0.94	0.81
PG 34:2; [M-H]-@5.30	ME184255	1.24	1.04	0.90	0.83
PS 39:6; [M-H]-@5.43	ME184286	1.27	1.07	0.87	0.79
plasmenyl-PE 34:2; [M-H]-@6.69	ME184299	1.18	1.06	0.83	0.93
PG 35:2; [M-H]-@5.64	ME184257	1.16	1.09	0.85	0.90
plasmenyl-PE 42:6; [M-H]-@7.75	ME184315	1.16	1.09	0.82	0.92
PE 42:9; [M-H]-@6.10	ME184249	1.19	1.01	0.85	0.95
PG 36:4; [M-H]-@4.88	ME184262	1.21	1.02	0.85	0.93
PC 30:1; [M-Ac-H]-@5.49	ME184181	1.20	1.01	0.90	0.90
PE 35:2; [M-H]-@6.70	ME184223	1.19	1.02	0.88	0.92
FFA(18:2)	ME184170	1.19	1.02	0.92	0.87
plasmenyl-PE 38:5; [M-H]-@6.73	ME184310	1.18	1.05	0.90	0.88
CL 70:5; [M-2H](2-)@9.21	ME184151	1.03	0.96	0.90	1.12
PG 38:2; [M-H]-@6.43	ME184263	1.05	0.93	0.89	1.14
PG 32:1; [M-H]-@5.15	ME184251	1.04	1.00	0.90	1.05
PC 32:1; [M-Ac-H]-@6.11	ME184184	1.01	0.95	0.96	1.08
PI 34:2; [M-H]-@5.15	ME184274	1.03	0.97	0.93	1.08
PG 36:0; [M-H]-@6.81	ME184258	1.07	0.84	1.10	0.99
plasmenyl-PE 40:4; [M-H]-@7.72	ME184312	1.12	0.84	1.04	1.01
CL 74:7; [M-2H](2-)@9.29	ME184160	1.16	0.85	0.96	1.03
CL 70:3; [M-2H](2-)@9.51	ME184149	1.11	0.89	0.97	1.04
PI 40:7; [M-H]-@5.17	ME184284	1.10	0.85	0.99	1.06
FFA(22:1)	ME184175	1.06	0.89	0.95	1.09
PS 38:4; [M-H]-@5.92	ME184285	1.03	0.92	1.04	1.01
PI 38:5; [M-H]-@5.31	ME184279	1.03	0.91	1.00	1.06
PI 40:6; [M-H]-@5.65	ME184283	1.04	0.90	1.01	1.05
PC 36:2; [M-Ac-H]-@6.91	ME184199	1.07	0.92	0.99	1.03
PE 42:7; [M-H]-@6.94	ME184247	1.05	0.94	0.98	1.03
PI 38:4; [M-H]-@5.72	ME184278	1.05	0.94	1.00	1.02
lysoPE 20:4; [M-H]-@1.30	ME184291	1.22	0.88	0.90	1.00
PI 38:6; [M-H]-@5.05	ME184280	1.19	0.90	0.90	1.00
PE 34:1; [M-H]-@6.80	ME184220	1.09	0.95	0.91	1.05
PI 36:4; [M-H]-@5.11	ME184276	1.13	0.92	0.89	1.07
PC 34:2; [M-Ac-H]-@6.24	ME184190	1.17	0.97	0.87	1.00
PE 36:5; [M-H]-@5.91	ME184227	1.18	0.97	0.85	1.00
PC 32:2; [M-Ac-H]-@5.65	ME184185	1.14	0.92	0.93	1.01
PE 36:2; [M-H]-@7.02	ME184225	1.15	0.93	0.93	0.99
PC 37:5; [M-Ac-H]-@6.03	ME184204	1.14	0.99	0.90	0.97
PI 36:2; [M-H]-@5.79	ME184275	1.13	0.96	0.92	0.99
plasmenyl-PE 38:6; [M-H]-@6.48	ME184311	1.13	0.97	0.90	1.00
PC 34:1; [M-Ac-H]-@6.71	ME184189	1.10	1.10	0.92	0.87
PE 38:6; [M-H]-@6.12	ME184235	1.12	1.09	0.92	0.87
CL 72:6; [M-2H](2-)@9.25	ME184155	1.13	1.06	0.94	0.87
PG 36:1; [M-H]-@6.36	ME184259	1.12	1.05	0.95	0.89
FFA(18:1)	ME184169	1.11	1.01	0.96	0.92
PC 35:2; [M-Ac-H]-@6.62	ME184193	1.10	1.00	0.98	0.92
PE 37:4; [M-H]-@6.66	ME184230	1.06	1.03	1.00	0.90
CL 72:8; [M-2H](2-)@8.86	ME184157	1.08	1.04	0.96	0.91
PE 40:8; [M-H]-@5.85	ME184244	1.07	1.07	0.96	0.89
PC 38:5; [M-Ac-H]-@6.37	ME184207	1.09	1.12	0.86	0.92
CL 72:7; [M-2H](2-)@9.03	ME184156	1.09	1.07	0.91	0.93
CL 74:8; [M-2H](2-)@9.14	ME184161	1.08	1.09	0.89	0.94
CL 72:5; [M-2H](2-)@9.43	ME184154	1.08	1.04	0.92	0.96
PE 36:3; [M-H]-@6.50	ME184226	1.12	1.03	0.92	0.93
plasmenyl-PE 32:0; [M-H]-@7.08	ME184294	1.12	1.04	0.89	0.95
PE 36:6; [M-H]-@5.57	ME184228	1.16	0.93	0.98	0.93
PC 42:10; [M-Ac-H]-@5.75	ME184214	1.13	0.95	0.99	0.93
PE 40:9; [M-H]-@5.49	ME184245	1.14	0.95	0.97	0.94
FFA(20:1)	ME184172	1.10	0.96	1.00	0.94
PE 38:4; [M-H]-@6.93	ME184233	1.10	0.93	1.02	0.94
FFA(22:0)	ME184174	1.06	0.97	0.95	1.02
PG 36:2; [M-H]-@5.92	ME184260	1.03	0.97	0.97	1.03
PG 38:6; [M-H]-@5.27	ME184267	1.10	0.98	0.95	0.96
FFA(20:0)	ME184171	1.07	0.98	0.97	0.98
PI 40:5; [M-H]-@5.95	ME184282	1.08	0.97	0.97	0.98
PC 36:3; [M-Ac-H]-@6.41	ME184200	1.06	1.01	0.97	0.95
FFA(16:0)	ME184167	1.04	0.99	0.98	0.98
FFA(18:0)	ME184168	1.02	1.00	0.98	0.99
PE 40:6; [M-H]-@6.88	ME184242	1.03	1.07	0.96	0.94
PC 34:3; [M-Ac-H]-@5.80	ME184191	1.04	1.02	0.93	1.01
PC 36:1; [M-Ac-H]-@7.39	ME184198	1.03	1.04	0.95	0.98
FFA(22:3)	ME184177	0.79	1.07	1.11	1.03
CL 76:11; [M-2H](2-)@8.97	ME184163	0.86	1.05	1.12	0.96
lysoPE 18:0; [M-H]-@2.42	ME184289	0.83	1.05	1.16	0.97
PC 40:6; [M-Ac-H]-@6.70	ME184211	0.83	1.03	1.15	0.98
PE 38:7; [M-H]-@5.73	ME184236	0.91	1.01	0.98	1.10
PG 33:1; [M-H]-@5.45	ME184253	0.87	1.03	1.00	1.11
CL 76:12; [M-2H](2-)@8.77	ME184164	0.90	1.04	1.06	0.99
PE 40:7; [M-H]-@6.25	ME184243	0.93	1.04	1.05	0.99
PC 40:7; [M-Ac-H]-@6.26	ME184212	0.94	0.96	1.08	1.02
PG 40:6; [M-H]-@5.89	ME184268	0.86	1.03	1.06	1.05
PC 35:5; [M-Ac-H]-@5.53	ME184196	0.91	0.97	1.06	1.06
PG 33:0; [M-H]-@5.98	ME184252	0.90	1.00	1.04	1.07
CL 70:4; [M-2H](2-)@9.38	ME184150	1.01	1.18	1.04	0.77
FFA(22:2)	ME184176	0.98	1.10	1.01	0.90
PC 39:6; [M-Ac-H]-@6.47	ME184209	0.98	1.12	1.00	0.90
PC 35:4; [M-Ac-H]-@5.96	ME184195	0.93	1.13	1.03	0.91
PE 42:8; [M-H]-@6.50	ME184248	0.95	1.11	1.02	0.93
PC 32:0; [M-Ac-H]-@6.66	ME184183	0.98	1.20	0.97	0.85
CL 74:9; [M-2H](2-)@8.99	ME184162	1.01	1.16	0.92	0.91
PE 40:5; [M-H]-@7.15	ME184241	1.04	1.13	0.97	0.86
lysoPE 22:5; [M-H]-@1.39	ME184292	1.11	0.89	1.13	0.87
FFA(20:2)	ME184173	1.12	0.97	1.06	0.85
PG 38:5; [M-H]-@5.43	ME184266	1.11	0.96	1.08	0.85
PC 40:5; [M-Ac-H]-@7.04	ME184210	0.93	1.03	1.11	0.93
PC 37:4; [M-Ac-H]-@6.56	ME184203	0.96	1.01	1.10	0.93
PE 39:4; [M-H]-@7.14	ME184237	0.96	1.02	1.11	0.91
PC 38:4; [M-Ac-H]-@6.83	ME184206	0.91	0.97	1.14	0.97
PE 37:2; [M-H]-@7.21	ME184229	0.95	0.97	1.16	0.93
PE 39:5; [M-H]-@6.76	ME184238	1.01	1.06	1.06	0.87
PG 36:3; [M-H]-@5.35	ME184261	1.02	1.07	1.07	0.84
PE 39:7; [M-H]-@6.06	ME184240	1.05	1.02	1.05	0.88
PS 41:6; [M-H]-@6.04	ME184288	1.02	1.00	1.08	0.90
plasmenyl-PE 40:6; [M-H]-@7.16	ME184314	1.02	0.94	1.07	0.96
PI 34:1; [M-H]-@5.60	ME184273	1.02	0.95	1.09	0.94
PS 40:6; [M-H]-@5.79	ME184287	1.03	0.94	1.08	0.94
PC 38:6; [M-Ac-H]-@6.03	ME184208	1.00	1.05	1.02	0.93
FFA(24:1)	ME184179	1.01	1.01	1.02	0.96
PC 36:4; [M-Ac-H]-@6.10	ME184201	1.00	0.99	1.05	0.95

Factors:

F1	Line:HCR \| Rest/Exercise:10 minutes Exercise
F2	Line:HCR \| Rest/Exercise:Rest
F3	Line:LCR \| Rest/Exercise:10 minutes Exercise
F4	Line:LCR \| Rest/Exercise:Rest

Data matrix